Linzess sales strength, apraglutide Phase III catalyst, FY2026 guidance and $5.37 target—read now for key upside drivers.

Our country did not cede the nuclear race to the Soviet Union, and we cannot cede the biotechnology race to China now.

On CGTxchange, sponsors can list their shelved cell and gene therapies in the hopes that other investors, partners, and ...

Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage Alzheimer’s disease (AD) therapy, AR-1001. The option fee plus license ...

MBC BioLabs sees its two biotech incubators location in San Francisco's Dogpatch neighborhood, near the AI hub of Mission Bay, as an advantage. It wants to build one more to prove the point.

LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed ...

Researchers at the São Carlos Institute of Physics at the University of São Paulo (IFSC-USP) in Brazil, led by Paulo Augusto ...

Sagimet Biosciences Inc. gets a Buy rating as denifanstat targets MASH & acne; key Phase 3 catalysts and funding risks ahead.

LAST May 8, the Southeast Asian Regional Center for Graduate Study and Research in Agriculture (Searca), based at Los Banos, Laguna, held a forum on how to “effectively respond to the triple shocks ...

A type of immune cell circulating in the blood contributes to cognitive ageing, and blocking its effects can reverse the ...

Metabolism as a Growth Driver No company currently demonstrates more impressively than Eli Lilly just how efficient it can be ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced significant updates to two ...